🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

126+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 126 recruiting trials for “small-cell-lung-cancer

Phase 3RecruitingNCT06627647

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

🏥 AstraZeneca📍 282 sites📅 Started Nov 2024View details ↗
Phase 1RecruitingNCT06685718

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

👨‍⚕️ Study Director, BeiGene📍 28 sites📅 Started Nov 2024View details ↗
RecruitingNCT06737107

Multicenter Analysis of Different Approaches in Segmentectomies in Early-stage Lung Cancer

🏥 Scientific Institute San Raffaele📍 4 sites📅 Started Nov 2024View details ↗
Phase 2RecruitingNCT06812871

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

🏥 Sun Yat-sen University📍 1 site📅 Started Nov 2024View details ↗
Phase 1, PHASE2RecruitingNCT06644768

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

🏥 Daiichi Sankyo📍 45 sites📅 Started Oct 2024View details ↗
Phase 1RecruitingNCT06562192

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

🏥 Novartis Pharmaceuticals📍 31 sites📅 Started Oct 2024View details ↗
Phase 1RecruitingNCT06598306

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

👨‍⚕️ MD, Amgen📍 30 sites📅 Started Oct 2024View details ↗
Phase 2RecruitingNCT05613452

Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer

👨‍⚕️ Jingfang Mao, PHD, Shanghai Proton and Heavy Ion Center📍 1 site📅 Started Sep 2024View details ↗
RecruitingNCT06538038

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

👨‍⚕️ Suzanne Cole, MD, UT Southwestern Simmons Comprehensive Cancer Center📍 146 sites📅 Started Sep 2024View details ↗
Phase 1, PHASE2RecruitingNCT06567015

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

🏥 Pierre Fabre Medicament📍 16 sites📅 Started Sep 2024View details ↗
Phase 1RecruitingNCT06596915

Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors

🏥 Shandong Boan Biotechnology Co., Ltd📍 1 site📅 Started Sep 2024View details ↗
Phase 1RecruitingNCT06476808

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

👨‍⚕️ Bristol-Myers Squibb, Bristol-Myers Squibb📍 16 sites📅 Started Sep 2024View details ↗
Phase 2RecruitingNCT06728865

Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

🏥 Li-kun Chen📍 1 site📅 Started Sep 2024View details ↗
Phase 1, PHASE2RecruitingNCT06283719

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

👨‍⚕️ Jason Wu, Suzhou Zelgen Biopharmaceuticals Co.,Ltd📍 1 site📅 Started Sep 2024View details ↗
Phase 2RecruitingNCT06311981

Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients

👨‍⚕️ Jingfang Mao, PHD, Shanghai Proton and Heavy Ion Center📍 1 site📅 Started Aug 2024View details ↗
Phase 1RecruitingNCT05963867

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

🏥 Boehringer Ingelheim📍 1 site📅 Started Aug 2024View details ↗
Phase 1RecruitingNCT06505824

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

👨‍⚕️ Caicun Zhou, Shanghai East Hospital📍 1 site📅 Started Aug 2024View details ↗
Phase 2RecruitingNCT06161532

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

👨‍⚕️ Andrea B Apolo, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Aug 2024View details ↗
Phase 2RecruitingNCT06517953

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

🏥 Sun Yat-sen University📍 1 site📅 Started Jul 2024View details ↗
Phase 2Enrolling by InvitationNCT06250777

Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases

👨‍⚕️ Hye Ryun Kim, Yonsei University Health system, Severance Hospital📍 1 site📅 Started Jul 2024View details ↗
← PreviousPage 3 of 7Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →